Nintedanib Ipf Stada

Nintedanib, the active ingredient in Nintedanib Ipf Stada, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain forms of non‑small cell lung cancer.

GNH USA supplies Nintedanib Ipf Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory‑compliant sourcing for global markets.

Nintedanib is used to target fibrotic lung disease and specific lung‑cancer pathways.

Idiopathic pulmonary fibrosis: slows disease progression and decline in lung function. Systemic sclerosis‑associated interstitial lung disease: reduces the rate of forced vital capacity loss. Non‑small cell lung cancer: inhibits tumor angiogenesis and growth when used in appropriate therapeutic regimens.

Nintedanib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease in the stomach, may lead to reduced appetite. - Vomiting: occasional episodes, usually self‑limited. - Elevated liver enzymes: mild increases in ALT/AST observed in routine monitoring.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring discontinuation. - Bleeding events: gastrointestinal or other hemorrhage, especially with anticoagulants. - Cardiovascular events: myocardial infarction or stroke in predisposed patients. - Severe infections: opportunistic infections in immunocompromised individuals. - Gastrointestinal perforation: rare but potentially life‑threatening.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters. - Liver function: assess baseline ALT/AST and monitor periodically. - Bleeding risk: avoid concomitant use with strong anticoagulants unless necessary. - Cardiovascular health: screen for history of ischemic heart disease or stroke. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with obstetric specialist. - Store below 25°C: keep in the original pack, protect from moisture.

Nintedanib may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - P‑gp inhibitors (e.g., verapamil): can raise plasma concentrations. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding. - St. John’s wort: potential reduction in drug levels. - High‑fat meals: may modestly affect absorption; advise consistent intake.